Open Access
Atypical Recurrence of Parathyroid Carcinoma Following Infliximab Therapy in a Patient with Ulcerative Colitis
Aace Clinical Case ReportsPeer ReviewedFelona Gunawan +12020Journals
Parathyroid carcinoma (PTC) has a high rate of recurrence, which typically occurs within 5 years of diagnosis involving locoregional sites. Immunosuppressive therapies pose a theoretical increased risk of malignancy. We report an atypical case of PTC recurrence in a patient receiving infliximab therapy for ulcerative colitis (UC).

The content you want is available to Zendy users.

Already have an account? Sign in
Having issues? Contact support